Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $103.21 (market cap $29.07B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 6× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 126 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LQD | TVTX | |
|---|---|---|
Market Cap | $29.07B | $4.88B |
Volume | 26,122,352 | 1,668,577 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $67.52 |
52-Week Low | $101.83 | $26.79 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.55, down slightly by 0.03% on the day, with technical indicators signaling a bearish trend as selling pressure outweighs buying. The ETF faces headwinds from rising bond yields and increased short interest, which grew 53.1% in September. Recent dividends of $0.44-$0.46 provide income support, but the overall market sentiment remains cautious amid a challenging fixed-income environment.
The outlook for LQD is constrained by persistent bond market volatility and higher interest rates, which pressure corporate bond valuations. While the ETF's investment-grade portfolio offers relative safety, further yield increases could limit upside. Key risks include Fed policy uncertainty and economic slowdown concerns, warranting a neutral to cautious stance for equity-focused investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
